Avant, Celldex merge in $115M stock deal

Avant Immunotherapeutics is merging with Celldex Therapeutics in a stock deal valued at $115 million. Celldex shareholders will wind up with a majority of the shares in the merged company, which will have development programs in vaccines and brain cancer immunotherapeutics. The merged company will also have a product on the market--the oral vaccine Rotarix. Celldex is privately held and Avant's shares closed at 55 cents on Friday.

- see this release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.